784 related articles for article (PubMed ID: 10971431)
1. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
3. The matrix metalloproteinase system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2006 Dec; 44(6):482-6. PubMed ID: 16338034
[TBL] [Abstract][Full Text] [Related]
4. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
5. Measuring gelatinase activity in colorectal cancer.
Baker EA; Leaper DJ
Eur J Surg Oncol; 2002 Feb; 28(1):24-9. PubMed ID: 11869009
[TBL] [Abstract][Full Text] [Related]
6. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and their inhibitors.
Kugler A
Anticancer Res; 1999; 19(2C):1589-92. PubMed ID: 10365151
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion.
Lamparter S; Schoppet M; Christ M; Pankuweit S; Maisch B
Am J Cardiol; 2005 May; 95(9):1065-9. PubMed ID: 15842972
[TBL] [Abstract][Full Text] [Related]
11. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
12. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
13. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
17. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis.
Papakonstantinou E; Dionyssopoulos A; Aletras AJ; Pesintzaki C; Minas A; Karakiulakis G
J Am Acad Dermatol; 2004 Oct; 51(4):526-33. PubMed ID: 15389186
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
